Argos Therapeutics is a biotechnology company established in 1997 and based in Durham, North Carolina. The company focuses on the development of immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. Argos Therapeutics conducts clinical trial programs for cancer and human immunodeficiency virus. Its product lineup includes AGS-0031 for metastatic renal cell carcinoma, AGS-0041 for HIV, CD83 soluble protein for transplant rejection/autoimmune disorders, Anti IFN-alpha monoclonal antibody2 for lupus, and regulatory T cell therapy3 for autoimmune disorders. Previously known as MERIX Bioscience, Inc., Argos Therapeutics secured a $1.50M investment in Post-IPO Equity at 10 January 2018. The investment was made by undisclosed investors. With its focus on addressing critical medical needs through innovative immunotherapy solutions, Argos Therapeutics is positioned to make a significant impact in the biotechnology and health care industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $1.50M | - | 10 Jan 2018 | |
| Post-IPO Equity | $60.00M | 2 |
|
15 Mar 2016 |
| Post-IPO Equity | $10.00M | - | 15 Apr 2015 | |
| Post-IPO Debt | $25.00M | 1 |
|
30 Sep 2014 |
| Series E | $17.50M | 10 |
|
20 Nov 2013 |
No recent news or press coverage available for Argos Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
